Table 3.
| Canonical pathways | Gonzalez 2018 | Braun 2020 |
|---|---|---|
| Category | Z score | |
| mTOR signaling | 1 | 1.633 |
| Ferroptosis signaling pathway | − 0.816 | − 0.816 |
| ERK5 signaling | − 0.447 | − 1 |
| Endocannabinoid cancer inhibition pathway | 1 | 0.333 |
| PPAR signaling | 1 | 0.302 |
| NRF2-mediated oxidative stress response | 0.447 | 0.447 |
| Upstream regulators | Gonzalez 2018 | Braun 2020 |
|---|---|---|
| Category | Z score | |
| ESR1 | − 2.927 | − 2.822 |
| CD24 | − 1.987 | − 3.308 |
| CPT1B | − 1.131 | − 3.582 |
| miR-30c-5p (and other miRNAs w/seed GUAAACA | 1.89 | 2.796 |
| PTPRR | − 1.987 | − 2.28 |
| ASPSCR1-TFE3 | 2.236 | 1.897 |
| CD38 | 1.987 | 2.123 |
| Mifepristone | 1.8 | 2.142 |
| PKD1 | 1.48 | 2.414 |
| AR | − 1.998 | − 1.842 |
| GSKJ4 | − 1.342 | − 2.449 |
| Firre | 2 | 1.706 |
| Tetraethylammonium | − 2 | − 1.633 |
| EGF | 1.85 | 1.694 |
| Valproic acid | − 1.37 | − 1.977 |
| TRAP1 | − 1.342 | − 2 |
| Pirinixic acid | 0.412 | 2.899 |
| FN1 | − 2.236 | − 1.014 |
| TCF4 | 1 | 2.1698 |
| XBP1 | 1.945 | 1.212 |
| ERBB2 | 2.709 | 0.358 |
| SYVN1 | 2.449 | 0.577 |
| TSC2 | − 1.564 | − 1.412 |
| Topotecan | 0.853 | 2.111 |
| BMP4 | 1.869 | 1.021 |
| Tamoxifen | 1.424 | 1.373 |
| Benzo(a)pyrene | 1.4 | 1.39 |
| SMARCA5 | − 0.378 | − 2.236 |
| IGF2BP1 | − 0.958 | − 1.633 |
| UBQLN2 | − 1.387 | − 0.816 |
| Mek | − 1.187 | − 0.982 |
| MYCL | − 1.98 | − 0.104 |
| KLF3 | 1.155 | 0.728 |
| Diseases and functions | ||
| Category | ||
| Morbidity or mortality | 1.118 | 3.865 |
| Organismal death | 1.039 | 3.671 |
| Congenital encephalopathy | 0.928 | 2.623 |
| Abdominal cancer | 1.557 | 1.972 |
| Abdominal neoplasm | 1.247 | 2.212 |
| Hematologic cancer | 0.872 | 2.544 |
| Abdominal carcinoma | 1.842 | 1.504 |
| Myeloid or lymphoid neoplasm | 0.492 | 2.764 |
| Neoplasia of blood cells | 0.377 | 2.84 |
| Formation of solid tumor | 1.952 | 1.223 |
| Solid tumor | 1.375 | 1.765 |
| Tumorigenesis of epithelial neoplasm | 1.635 | 1.475 |
| Malignant solid organ tumor | − 1.091 | − 1.969 |
| Intraabdominal organ tumor | 0.976 | 2.081 |
| Skin cancer | − 1.067 | − 1.98 |
| Development of digestive organ tumor | 1.238 | 1.709 |
| Frequency of tumor | 1.687 | 1.181 |
| Non-melanoma solid tumor | 1.217 | 1.643 |
| Cancer | 1.178 | 1.298 |
| Malignant solid tumor | 1.456 | 0.981 |
| Extracranial solid tumor | 1.098 | 1.309 |
| Growth failure or short stature | 0.16 | 2.221 |
| Incidence of tumor | 1.183 | 1.175 |
| Development of malignant tumor | 1.368 | 0.849 |
| Digestive organ tumor | 0.588 | 1.587 |
| Malignant genitourinary solid tumor | 1.719 | 0.437 |
| Infection by RNA virus | 1.067 | 0.994 |
| Infection of cells | 1.319 | 0.716 |
| Development of carcinoma | 1.3 | 0.623 |
| Infection by HIV-1 | 1.11 | 0.729 |
| HIV infection | 1.11 | 0.729 |
| Digestive system cancer | 0.368 | 1.46 |
| Viral infection | 0.448 | 1.367 |
| Head and neck tumor | − 1.308 | − 0.437 |
| Skin tumor | − 1.069 | − 0.634 |
| Brain lesion | − 0.911 | − 0.681 |
| Renal lesion | 0.651 | 0.883 |
| Urinary tract tumor | 0.152 | 1.342 |
| Anogenital cancer | 1.193 | 0.269 |
| Connective or soft tissue tumor | 1.331 | 0.113 |
| Development of urinary tract | − 0.97 | − 0.391 |
| Infection of embryonic cell lines | 0.137 | 1.213 |
| Genital tumor | 0.446 | 0.763 |
| Pelvic tumor | 0.11 | 1.04 |
Activation z‐score represents the inferred activation states of predicted transcriptional regulators based on the IPA molecular network. Positive values = activated in male and/or inhibited in female, negative values = activated in female and/or inhibited in male, (IPA version update 12/13/2020)